Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

EPIGRAL vs TATVA CHINTAN PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    EPIGRAL TATVA CHINTAN PHARMA EPIGRAL/
TATVA CHINTAN PHARMA
 
P/E (TTM) x 23.2 67.0 34.7% View Chart
P/BV x 4.3 4.9 86.8% View Chart
Dividend Yield % 0.5 0.2 246.3%  

Financials

 EPIGRAL   TATVA CHINTAN PHARMA
EQUITY SHARE DATA
    EPIGRAL
Mar-23
TATVA CHINTAN PHARMA
Mar-23
EPIGRAL/
TATVA CHINTAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7372,649 65.6%   
Low Rs8111,606 50.5%   
Sales per share (Unadj.) Rs526.7191.1 275.6%  
Earnings per share (Unadj.) Rs85.020.5 414.4%  
Cash flow per share (Unadj.) Rs111.324.8 448.1%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Avg Dividend yield %0.40.1 417.6%  
Book value per share (Unadj.) Rs257.3232.2 110.8%  
Shares outstanding (eoy) m41.5522.17 187.4%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.411.1 21.7%   
Avg P/E ratio x15.0103.7 14.4%  
P/CF ratio (eoy) x11.485.7 13.4%  
Price / Book Value ratio x4.99.2 54.0%  
Dividend payout %5.99.7 60.3%   
Avg Mkt Cap Rs m52,91847,157 112.2%   
No. of employees `000NANA-   
Total wages/salary Rs m689386 178.4%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m21,8844,236 516.6%  
Other income Rs m9357 161.8%   
Total revenues Rs m21,9774,294 511.9%   
Gross profit Rs m6,889572 1,204.6%  
Depreciation Rs m1,09096 1,140.3%   
Interest Rs m66886 776.9%   
Profit before tax Rs m5,225448 1,166.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,692-7 -23,893.8%   
Profit after tax Rs m3,533455 776.7%  
Gross profit margin %31.513.5 233.2%  
Effective tax rate %32.4-1.6 -2,047.9%   
Net profit margin %16.110.7 150.3%  
BALANCE SHEET DATA
Current assets Rs m4,1953,136 133.8%   
Current liabilities Rs m6,4772,361 274.3%   
Net working cap to sales %-10.418.3 -57.1%  
Current ratio x0.61.3 48.8%  
Inventory Days Days83 288.2%  
Debtors Days Days27773 381.4%  
Net fixed assets Rs m20,1274,304 467.7%   
Share capital Rs m416222 187.5%   
"Free" reserves Rs m10,2764,926 208.6%   
Net worth Rs m10,6915,148 207.7%   
Long term debt Rs m5,44642 12,875.7%   
Total assets Rs m24,3227,439 326.9%  
Interest coverage x8.86.2 142.1%   
Debt to equity ratio x0.50 6,199.9%  
Sales to assets ratio x0.90.6 158.0%   
Return on assets %17.37.3 237.6%  
Return on equity %33.08.8 374.0%  
Return on capital %36.510.3 355.1%  
Exports to sales %5.276.2 6.8%   
Imports to sales %056.9 0.0%   
Exports (fob) Rs m1,1423,229 35.4%   
Imports (cif) Rs mNA2,409 0.0%   
Fx inflow Rs m1,1423,229 35.4%   
Fx outflow Rs m3,2952,409 136.8%   
Net fx Rs m-2,153820 -262.7%   
CASH FLOW
From Operations Rs m6,262278 2,253.8%  
From Investments Rs m-4,372-1,011 432.3%  
From Financial Activity Rs m-1,998378 -528.6%  
Net Cashflow Rs m-108-357 30.4%  

Share Holding

Indian Promoters % 71.4 72.0 99.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.2 17.3 7.2%  
FIIs % 1.2 4.2 27.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 28.6 28.0 102.3%  
Shareholders   92,959 74,519 124.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare EPIGRAL With:   PIDILITE INDUSTRIES    SRF    BALAJI AMINES    YASHO INDUSTRIES    GHCL    


More on EPIGRAL vs TATVA CHINTAN PHARMA

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

EPIGRAL vs TATVA CHINTAN PHARMA Share Price Performance

Period EPIGRAL TATVA CHINTAN PHARMA
1-Day -0.27% 0.48%
1-Month -8.52% -11.67%
1-Year 34.03% -33.66%
3-Year CAGR 39.28% -22.40%
5-Year CAGR 21.99% -14.12%

* Compound Annual Growth Rate

Here are more details on the EPIGRAL share price and the TATVA CHINTAN PHARMA share price.

Moving on to shareholding structures...

The promoters of EPIGRAL hold a 71.4% stake in the company. In case of TATVA CHINTAN PHARMA the stake stands at 72.0%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of EPIGRAL and the shareholding pattern of TATVA CHINTAN PHARMA.

Finally, a word on dividends...

In the most recent financial year, EPIGRAL paid a dividend of Rs 5.0 per share. This amounted to a Dividend Payout ratio of 5.9%.

TATVA CHINTAN PHARMA paid Rs 2.0, and its dividend payout ratio stood at 9.7%.

You may visit here to review the dividend history of EPIGRAL, and the dividend history of TATVA CHINTAN PHARMA.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.